...ioma immunotherapy, nivolumab ipilimumab, mesothelioma clinical trial, FDA approval 2020, Dr. Paul Baas, mesothelioma treatment
...e="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approval
...
21 KB (2,642 words) - 09:18, 6 April 2026
...helioma research milestones from 1767 discovery through 2020 immunotherapy approval to current CAR-T and gene therapy research.
...imeline, mesothelioma history, asbestos cancer history, CheckMate 743, FDA approval mesothelioma, mesothelioma research milestones
...
20 KB (2,490 words) - 20:57, 20 February 2026
...doubled from 8.8 months to 18.1 months. These findings led directly to FDA approval in October 2020, transforming treatment options for mesothelioma patients w
| style="padding:10px;" | FDA Approval Date
...
27 KB (3,530 words) - 04:00, 9 March 2026
= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, $100,000-$400,000 Annual Expenses, and Financial Recove
...l of 18.1-23 months compared to 12-14 months with chemotherapy alone. Four FDA-approved treatment pathways exist as of 2025: traditional chemotherapy, imm
...
33 KB (3,904 words) - 20:57, 20 February 2026
|title=Immunotherapy for Mesothelioma: CheckMate 743, Clinical Trials & FDA-Approved Treatment
...ve guide to immunotherapy for malignant pleural mesothelioma including the FDA-approved nivolumab plus ipilimumab combination, CheckMate 743 trial results
...
36 KB (4,570 words) - 09:56, 6 April 2026
...t established immunotherapy as the new standard of care in 2020.<ref name="fda-nivo-ipi" /> Today, researchers are exploring CAR-T cell therapy, gene ther
...months or longer with modern multimodal treatment approaches. The 2020 FDA approval of nivolumab plus ipilimumab marked the first new systemic therapy for meso
...
38 KB (4,755 words) - 03:42, 9 March 2026
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approved
...apy backbone for epithelioid disease.<ref name="emphacis" /><ref name="fda-approval" /> Although dual immune checkpoint blockade with nivolumab plus ipilimumab
...
48 KB (5,851 words) - 22:11, 8 March 2026
|title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA Approval & Treatment Guide
...mesothelioma. Covers STELLAR trial results (18.2-month median OS), FDA HDE approval, mechanism of action, treatment protocol, side effects, cost, and current g
...
64 KB (8,231 words) - 09:57, 6 April 2026
...isease, and cellular therapies demonstrating unprecedented durability. The FDA approved '''pembrolizumab plus chemotherapy''' in September 2024 as a new f
...2% response with pembrolizumab-chemo vs 29% with chemo alone''' — the 2024 FDA-approved combination nearly doubles confirmed response rates in first-line
...
39 KB (4,791 words) - 23:07, 10 March 2026
...hensive guide to blood test early detection for mesothelioma including the FDA-approved MESOMARK assay, SOMAmer 13-protein panel, calretinin prediagnostic
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Test
...
39 KB (5,116 words) - 10:12, 6 April 2026
...ioma|Immunotherapy]] drugs including nivolumab and ipilimumab received FDA approval for unresectable mesothelioma and have shown improved survival.<ref name="i
...
11 KB (1,457 words) - 21:27, 20 February 2026
...mprehensive guide to blood-based biomarkers for mesothelioma including the FDA-approved MESOMARK assay, fibulin-3, osteopontin, HMGB1, SOMAmer panel, and
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Test
...
38 KB (4,844 words) - 09:56, 6 April 2026
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Regimens
...arginine depletion therapy (BLA under FDA review), tumor treating fields (FDA-approved under Humanitarian Device Exemption), and mesothelin-targeted CAR-
...
55 KB (6,918 words) - 12:35, 6 April 2026
...over the course of treatment.<ref name="pmc6637828" /> Since the 2020 FDA approval of immunotherapy (Opdivo + Yervoy) as a first-line treatment, average per-p
...
14 KB (1,830 words) - 09:56, 6 April 2026
...le CAR-T therapy has transformed the treatment of blood cancers — with six FDA-approved products achieving complete response rates as high as 90% in B-cel
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved for Meso
...
66 KB (8,673 words) - 02:53, 4 March 2026
| '''Mesothelin Biomarker Accuracy''' || 61% sensitivity, 87% specificity; FDA-approved diagnostic marker<ref name="biomarkerdata" />
...' || Immunotherapy median OS 18.1 months vs. 14.1 months for chemotherapy; FDA approved October 2020<ref name="checkmate743" />
...
43 KB (5,354 words) - 03:51, 9 March 2026
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Treatments
...mesonet-pleural" /> Despite advances in treatment — including the landmark approval of immunotherapy combinations in 2020 and 2024 — the overall '''5-year surv
...
59 KB (7,425 words) - 01:11, 6 April 2026
* '''Immunotherapy:''' Opdivo (nivolumab) plus Yervoy (ipilimumab) FDA-approved 2020
...patients today have more treatment options than ever before. The 2020 FDA approval of immunotherapy and ongoing [[Clinical Trials|clinical trials]] offer hope
...
25 KB (3,138 words) - 20:56, 20 February 2026
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved
* ONCOS-102, an oncolytic adenovirus expressing GM-CSF, received FDA fast-track designation in 2021 after showing median overall survival of 20.
...
67 KB (8,763 words) - 09:18, 6 April 2026
...lioma]] — Treatment paradigm shift 2020-2026: CheckMate 743, pembrolizumab approval, MARS 2 trial, CAR-T therapy
* '''2004''' — FDA approves pemetrexed, the first mesothelioma chemotherapy
...
23 KB (2,626 words) - 01:08, 6 April 2026
